Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
J Nucl Med. 2013 Jan;54(1):104-10. doi: 10.2967/jnumed.112.109397.
Previously, we reported a small-molecular-weight peptide, single amino acid chelae((99m)Tc)-conjugated phosphatidylserine-binding peptide (SAAC((99m)Tc)-PSBP-6), with high binding affinity to phosphatidylserine on the surface of apoptotic cells. The purpose of this study was to determine the effectiveness of SAAC((99m)Tc)-PSBP-6 in detecting apoptosis induced by chemotherapy.
B16/F10 melanoma and 38C13 lymphoma tumor models were used in this study. For each type of tumor model, mice were divided into a group treated for imaging (treated group [TG]) and a control group that was not treated (nontreated group [N-TG]). In the TG, mice bearing murine B16/F10 melanoma received a single dose of intravenous polymeric paclitaxel (equivalent dose, 80 mg/kg), and mice bearing 38C13 xenografts received intraperitoneal cyclophosphamide (100 mg/kg). Mice in the N-TG were given the same volume of saline. γ-imaging 4 h after intravenous injection of SAAC((99m)Tc)-PSBP-6 and small-animal PET 1 h after intravenous injection of (18)F-FDG were performed before chemotherapy and at 1 d after chemotherapy. On day 1, immediately after the apoptosis imaging sessions, 3 mice each in the TGs and N-TGs were killed, and tumor tissues were excised for hematoxylin and eosin histology, autoradiography, and immunohistochemical staining using anti-active caspase 3 and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). The tumor volumes in the remaining mice (n = 5/group) were measured every other day for 7 d.
In both tumor models, the uptake of SAAC((99m)Tc)-PSBP-6 increased significantly on day 1 after treatment, whereas (18)F-FDG uptake decreased significantly during the same time. The mean tumor uptake values for SAAC((99m)Tc)-PSBP-6 increased 142.4% ± 36.9% and 112% ± 42.9% in 38C13 and B16/F10 tumors, respectively (both P < 0.05, pretreatment vs. day 1 after treatment). The mean tumor uptake value for (18)F-FDG decreased 67.36% ± 17.52% and 62.82% ± 4.53% in 38C13 and B16/F10 tumors, respectively. The uptake of SAAC((99m)Tc)-PSBP-6 negatively correlated with (18)F-FDG (r = -0.79, P < 0.05). Treated tumors had smaller volumes than untreated controls, treated tumors had significantly higher numbers of apoptotic cells, and tumor uptake of SAAC((99m)Tc)-PSBP-6 correlated with the number of TUNEL-positive cells.
SAAC((99m)Tc)-PSBP-6 γ-imaging is useful for the early assessment of treatment-induced apoptosis and, thus, may be used as a substitute for (18)F-FDG PET for assessing early treatment response.
确定小分子肽,即单氨基酸螯合((99m)Tc)-连接的磷脂酰丝氨酸结合肽(SAAC((99m)Tc)-PSBP-6)在检测化疗诱导的细胞凋亡中的有效性。
本研究使用 B16/F10 黑色素瘤和 38C13 淋巴瘤肿瘤模型。对于每种肿瘤模型,将小鼠分为接受成像治疗的组(治疗组[TG])和未接受治疗的对照组(未治疗组[N-TG])。在 TG 中,携带 B16/F10 黑色素瘤的小鼠接受单次静脉注射聚紫杉醇(等效剂量 80mg/kg),携带 38C13 异种移植物的小鼠接受腹腔注射环磷酰胺(100mg/kg)。N-TG 中的小鼠给予相同体积的生理盐水。在化疗前和化疗后 1 小时进行 SAAC((99m)Tc)-PSBP-6 静脉注射后的γ-成像和(18)F-FDG 静脉注射后的小动物 PET。在第 1 天,在 TG 和 N-TG 的每组 3 只小鼠中立即进行凋亡成像,切除肿瘤组织进行苏木精和伊红组织学、放射性自显影和抗活性半胱天冬酶 3 和末端脱氧核苷酸转移酶介导的 dUTP 缺口末端标记(TUNEL)的免疫组织化学染色。剩余小鼠(每组 n=5)的肿瘤体积每两天测量一次,持续 7 天。
在两种肿瘤模型中,治疗后第 1 天 SAAC((99m)Tc)-PSBP-6 的摄取显著增加,而同一时间(18)F-FDG 的摄取显著减少。SAAC((99m)Tc)-PSBP-6 的肿瘤摄取均值在 38C13 和 B16/F10 肿瘤中分别增加了 142.4%±36.9%和 112%±42.9%(均 P<0.05,预处理与治疗后第 1 天相比)。(18)F-FDG 的肿瘤摄取均值在 38C13 和 B16/F10 肿瘤中分别降低了 67.36%±17.52%和 62.82%±4.53%。SAAC((99m)Tc)-PSBP-6 的摄取与(18)F-FDG 呈负相关(r=-0.79,P<0.05)。治疗肿瘤的体积小于未治疗对照肿瘤,治疗肿瘤的凋亡细胞数量明显更多,SAAC((99m)Tc)-PSBP-6 的肿瘤摄取与 TUNEL 阳性细胞数量相关。
SAAC((99m)Tc)-PSBP-6 γ 成像可用于早期评估治疗诱导的细胞凋亡,因此可替代(18)F-FDG PET 评估早期治疗反应。